BioSpace News Archive

AVROBIO to Present at Three Upcoming Investor Conferences in March

— Achieved Favorable Clinical Results Across Four First-in-Class Gene Therapy Programs for Danon Disease, FA, LAD-I and PKD — — Announced >50% Protein Expression with Stabilization and Biomarker Improvement Including Cardiac Output in Low Dose Cohort for Danon Disease Heart Failure Program —

CardioFocus, Inc., a medical device company dedicated to advancing ablation treatment for atrial fibrillation (AFib), announced today that results from its HeartLight® X3 Pivotal Study were published in the premier journal Circulation: Arrhythmia and Electrophysiology (CircEP),

NLS Pharmaceutics Ltd. (Nasdaq: NLSP, NLSPW), a clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer , Chief Executive Officer and Co-Founder, is scheduled to present at the following upcoming investor conferences

Health leader makes remote monitoring accessible and simple with cellular-connected smart scales and blood pressure monitors that require no setup and seamlessly transmit data to professionals

Informa Markets – Engineering, organizers of BIOMEDevice and Medical Design & Manufacturing (MD&M), North America’s two largest medical events, today announced MD&M | BIOMEDigital, a two-day virtual conference and exhibition fully dedicated to progressing innovation within digital health, 3D printing, software and security, surgical robotics, medical device design and product development, and more.

Aimmune Therapeutics, a Nestlé Health Science company developing and commercializing treatments for potentially life-threatening food allergies, today announced new clinical data from a pooled analysis of three controlled phase 3 (PALISADE1, RAMSES, ARTEMIS2) and three open-label extension

PureTech Health plc (Nasdaq: PRTC, LSE: PRTC) (“PureTech” or the “Company”), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercializing highly differentiated medicines for devastating diseases, today announced the publication of a research paper in the Journal of Controlled Release.

Co-Diagnostics, Inc. (Nasdaq: CODX), a molecular diagnostics company with a unique, patented platform for the development of diagnostic tests, announced today that laboratory partner Clinical Reference Laboratory’s (CRL) FDA-authorized Rapid Response COVID-19 Saliva Test, which uses Co-Diagnostics CoPrimer™ technology,

Adial Pharmaceuticals, Inc. (NASDAQ: ADIL; ADILW), a clinical-stage biopharmaceutical company focused on the development of treatments for addictions, today announced that it has reached 50% enrollment in the Company’s landmark ONWARD™ pivotal Phase 3 clinical trial.